SRR12475170
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.610
- E2F_TARGETS+0.450
- MYC_TARGETS_V1+0.450
- OXIDATIVE_PHOSPHORYLATION+0.310
- DNA_REPAIR+0.300
- G2M_CHECKPOINT+0.280
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.260
- ADIPOGENESIS+0.200
- HEDGEHOG_SIGNALING+0.200
- WNT_BETA_CATENIN_SIGNALING+0.180
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.500
- TGF_BETA_SIGNALING-0.380
- KRAS_SIGNALING_UP-0.370
- ALLOGRAFT_REJECTION-0.360
- INFLAMMATORY_RESPONSE-0.350
- IL6_JAK_STAT3_SIGNALING-0.340
- INTERFERON_GAMMA_RESPONSE-0.340
- COMPLEMENT-0.330
- PANCREAS_BETA_CELLS-0.330
- IL2_STAT5_SIGNALING-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2208894 | — | — | 0.858 |
| 2 | SRR17866857 | — | — | 0.848 |
| 3 | SRR10900551 | — | — | 0.846 |
| 4 | MDT-AP-1377 | Med | Medulloblastoma | 0.846 |
| 5 | TCGA-CV-5432-01A-02R-1686-07 | — | — | 0.844 |
| 6 | 79227609-ce40-4cf9-a9eb-16732cc2bfc5 | — | — | 0.841 |
| 7 | MDT-AP-2388 | Med | Medulloblastoma | 0.841 |
| 8 | a7d1fe23-5255-4daa-a6a9-fe2f67491323 | — | — | 0.839 |
| 9 | TCGA-E2-A2P5-01A-11R-A19W-07 | — | B | 0.834 |
| 10 | SRR2932827 | — | — | 0.833 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.610 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.280 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.260 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| PEROXISOME | 0.160 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.130 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.110 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.070 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.060 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.050 | Remibrutinib | — uncovered |